Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dabrafenib or trametinib in pediatric Langerhans cell histiocytosis with bone lesions: a retrospective efficacy and safety study.

BMC cancer - 30 Mar 2026

Ouyang Haiping, Yao Hailun, He Chengyuan, Zhou Yu, Dai Jiacheng, Wang Xiaohan, Zeng Jiarong, Liu Chenyuan, Zhong Kai, Xiao Jianwen, Liu Xing

Abstract excerpt

BACKGROUND: This study evaluated the efficacy and safety of dabrafenib or trametinib in pediatric Langerhans cell histiocytosis (LCH) patients with skeletal involvement, for whom conventional therapies offer limited benefit. METHODS: A single-center retrospective analysis was conducted on 30 children with pathologically confirmed, bone-involved LCH who received dabrafenib or trametinib due to severe, refractory,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Child

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Child, Preschool

Share to BRAF gene

Share to Infant

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41913125
DOI: 10.1186/s12885-026-15940-4
PMCID: PMC13169870

Genes

BRAF
MAP2K1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dabrafenib or trametinib in pediatric Langerhans cell histiocytosis with bone lesions: a retrospective efficacy and safety study.PMID 41913125Read ↗

Targeted therapy for Langerhans cell histiocytosis with maxillofacial involvement in 20 children.Semantic proximity Read ↗

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.Semantic proximity Read ↗

Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement.Semantic proximity Read ↗

BRAF Mutated LCH: Diagnosis and Treatment Challenges - A High-Risk Case Presentation and Discussion.Semantic proximity Read ↗

Adult-onset Langerhans cell histiocytosis of bone: A case series highlighting a rare entity.Semantic proximity Read ↗

Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children.Semantic proximity Read ↗

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.Semantic proximity Read ↗

Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.Semantic proximity Read ↗

Clinical and prognostic features of Langerhans cell histiocytosis in adults.Semantic proximity Read ↗

Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.Semantic proximity Read ↗

Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.